More than 3 million adults in Ohio (nearly 37% of our population!) live with obesity. This is not a personal failing; it is a complex, chronic disease crisis that is worsening each year and demands a focused, statewide intervention.

Fortunately, we are entering an era of unprecedented medical advancement. The advent of GLP-1 receptor agonists is a game-changer. As an obesity care physician, I see firsthand how these innovative medications transform lives by reducing the risk of diabetes, heart disease, and stroke while supporting weight management.

Originally published on ohiocapitaljournal.com, part of the BLOX Digital Content Exchange.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.